$IOVA
IOVANCE BIOTHERAPEUTICS, INC. Stock $iova

$iova Overview Financials Valuation SEC Filings Company Website

2019 Q2 Form 10-Q Financial Statement

#000114420419024279 Filed on May 07, 2019

Income Statement

Concept	2019 Q2	2019 Q1	2018 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$10.87M	$9.080M	$7.530M
YoY Change	59.15%	30.27%	-11.31%
% of Gross Profit
Research & Development	$39.30M	$30.91M	$27.42M
YoY Change	60.07%	55.21%	55.88%
% of Gross Profit
Depreciation & Amortization	$290.0K	$271.0K	$260.0K
YoY Change	31.82%	17.83%	8.33%
% of Gross Profit
Operating Expenses	$50.17M	$39.99M	$34.94M
YoY Change	59.87%	48.77%	34.02%
Operating Profit	-$50.17M	-$39.99M
YoY Change	59.87%	48.77%
Interest Expense	$2.610M	$3.040M	$2.370M
YoY Change	262.5%	744.44%	977.27%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$47.55M	-$36.95M	-$32.58M
YoY Change	55.09%	39.33%	26.03%
Income Tax
% Of Pretax Income
Net Earnings	-$47.55M	-$36.95M	-$32.58M
YoY Change	55.09%	39.36%	26.0%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$384.8K	-$299.4K	-$273.0K
COMMON SHARES
Basic Shares Outstanding	123.5M	123.4M	123.2M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q2	2019 Q1	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$404.2M	$440.0M	$468.5M
YoY Change	46.4%	48.1%	222.21%
Cash & Equivalents	$76.91M	$54.09M	$82.15M
Short-Term Investments	$327.2M	$385.9M	$386.4M
Other Short-Term Assets	$6.800M	$4.700M	$6.900M
YoY Change	83.78%	-16.07%	76.92%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$410.9M	$444.8M	$475.4M
YoY Change	46.88%	46.93%	218.42%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.472M	$3.504M	$2.683M
YoY Change	65.26%	59.27%	9.51%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.345M	$3.288M	$2.764M
YoY Change	47.75%	44.53%	-23.92%
Total Long-Term Assets	$24.99M	$16.75M	$5.447M
YoY Change	402.74%	272.2%	-10.46%
TOTAL ASSETS
Total Short-Term Assets	$410.9M	$444.8M	$475.4M
Total Long-Term Assets	$24.99M	$16.75M	$5.447M
Total Assets	$435.9M	$461.5M	$480.8M
YoY Change	53.09%	50.23%	209.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.78M	$7.589M	$2.739M
YoY Change	146.0%	14.98%	122.32%
Accrued Expenses	$13.57M	$8.489M	$11.66M
YoY Change	51.01%	4.8%	39.41%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$33.84M	$22.14M	$14.40M
YoY Change	138.58%	50.59%	50.06%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$53.00K	$53.00K	$230.0K
YoY Change			-23.33%
Total Long-Term Liabilities	$4.666M	$4.433M	$230.0K
YoY Change			-22.56%
TOTAL LIABILITIES
Total Short-Term Liabilities	$33.84M	$22.14M	$14.40M
Total Long-Term Liabilities	$4.666M	$4.433M	$230.0K
Total Liabilities	$38.50M	$26.57M	$14.63M
YoY Change	171.14%	80.75%	47.88%
SHAREHOLDERS EQUITY
Retained Earnings	-$457.6M	$300.0K	-$372.8M
YoY Change	49.36%	-100.11%	49.59%
Common Stock	$5.000K	$5.000K	$5.000K
YoY Change	25.0%		66.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$397.4M	$434.9M	$466.2M
YoY Change
Total Liabilities & Shareholders Equity	$435.9M	$461.5M	$480.8M
YoY Change	53.09%	50.21%	209.46%

Cashflow Statement

Concept	2019 Q2	2019 Q1	2018 Q4
OPERATING ACTIVITIES
Net Income	-$47.55M	-$36.95M	-$32.58M
YoY Change	55.09%	39.36%	26.0%
Depreciation, Depletion And Amortization	$290.0K	$271.0K	$260.0K
YoY Change	31.82%	17.83%	8.33%
Cash From Operating Activities	-$33.80M	-$29.09M	-$31.55M
YoY Change	41.3%	62.98%	50.52%
INVESTING ACTIVITIES
Capital Expenditures	-$1.440M	$824.0K	-$300.0K
YoY Change	242.86%	3645.45%	-600.0%
Acquisitions
YoY Change
Other Investing Activities	$60.11M	$1.860M	-$206.1M
YoY Change	-299.83%
Cash From Investing Activities	$58.69M	$1.033M	-$206.4M
YoY Change	-292.43%	-4795.45%	-344066.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00	$236.7M
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.380M	-2.000K	239.4M
YoY Change	0.6%	-100.0%	8153.45%
NET CHANGE
Cash From Operating Activities	-33.80M	-29.09M	-31.55M
Cash From Investing Activities	58.69M	1.033M	-206.4M
Cash From Financing Activities	3.380M	-2.000K	239.4M
Net Change In Cash	28.27M	-28.06M	1.420M
YoY Change	-155.37%	-118.5%	-107.89%
FREE CASH FLOW
Cash From Operating Activities	-$33.80M	-$29.09M	-$31.55M
Capital Expenditures	-$1.440M	$824.0K	-$300.0K
Free Cash Flow	-$32.36M	-$29.91M	-$31.25M
YoY Change	37.7%	67.39%	48.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-372760000
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54093000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	82152000
CY2019Q1	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	385925000
CY2018Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	386371000
CY2019Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4735000
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6640000
CY2019Q1	us-gaap	Assets Current AssetsCurrent	444753000
CY2018Q4	us-gaap	Assets Current AssetsCurrent	475163000
CY2019Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3504000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2683000
CY2019Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3288000
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2975000
CY2019Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	7589000
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2739000
CY2019Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8489000
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11659000
CY2019Q1	us-gaap	Liabilities Current LiabilitiesCurrent	22137000
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14398000
CY2019Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4433000
CY2018Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	230000
CY2019Q1	us-gaap	Liabilities Liabilities	26570000
CY2018Q4	us-gaap	Liabilities Liabilities	14628000
CY2019Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q1	us-gaap	Common Stock Value CommonStockValue	5000
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	5000
CY2019Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	138000
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-42000
CY2019Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	844789000
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	838984000
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-410006000
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	480821000
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	461502000
CY2019Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	71000
CY2018Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	62000
CY2019Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0
CY2019Q1	us-gaap	Revenues Revenues	0
CY2018Q1	us-gaap	Revenues Revenues	0
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30905000
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19912000
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9081000
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6965000
CY2019Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	3036000
CY2018Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	362000
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	123415
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	84350
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-26515000
CY2019Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	271000
CY2018Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	228000
CY2019Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0
CY2018Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-9000
CY2019Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-1232000
CY2018Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5846000
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4104000
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4582000
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5239000
CY2019Q1	iova	Increasedecrease In Operating Lease Liability IncreasedecreaseInOperatingLeaseLiability	-3346000
CY2018Q1	iova	Increasedecrease In Operating Lease Liability IncreasedecreaseInOperatingLeaseLiability	-546000
CY2019Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	91042000
CY2018Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0
CY2019Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	89185000
CY2018Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	0
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	824000
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22000
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1033000
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22000
CY2018Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1826000
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	69000
CY2018Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5630000
CY2019Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2018Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	162186000
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2000
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	169580000
CY2019Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-28059000
CY2018Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	151709000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	145373000
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	297082000
CY2019Q1	iova	Leasehold Improvements Paid By Landlord LeaseholdImprovementsPaidByLandlord	268000
CY2018Q1	iova	Leasehold Improvements Paid By Landlord LeaseholdImprovementsPaidByLandlord	12000
CY2019Q1	iova	Offering Costs Under Accounts Payable And Accrued Expenses OfferingCostsUnderAccountsPayableAndAccruedExpenses	0
CY2018Q1	iova	Offering Costs Under Accounts Payable And Accrued Expenses OfferingCostsUnderAccountsPayableAndAccruedExpenses	-93000
CY2018Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	9.97
CY2018Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	236700000
CY2019Q1	us-gaap	Short Term Investments ShortTermInvestments	385900000
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15284103
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20850266
CY2019Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	385925000
CY2018Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	368371000
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	5846000
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	4104000
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	5846000
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	4104000
CY2019Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	385925000
CY2018Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	386371000
CY2019Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	383841000
CY2019Q1	iova	Available For Sale Securities Accumulated Accretion AvailableForSaleSecuritiesAccumulatedAccretion	1946000
CY2019Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	156000
CY2019Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	18000
CY2019Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	385925000
CY2018Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	385272000
CY2018Q4	iova	Available For Sale Securities Accumulated Accretion AvailableForSaleSecuritiesAccumulatedAccretion	1141000
CY2018Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	40000
CY2018Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	82000
CY2019Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	2225000
CY2018Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	4113000
CY2019Q1	iova	Legal And Related Services Current LegalAndRelatedServicesCurrent	1033000
CY2018Q4	iova	Legal And Related Services Current LegalAndRelatedServicesCurrent	825000
CY2019Q1	iova	Clinical Related Expenses Current ClinicalRelatedExpensesCurrent	2560000
CY2018Q4	iova	Clinical Related Expenses Current ClinicalRelatedExpensesCurrent	3424000
CY2019Q1	iova	Manufacturing Related Expenses Current ManufacturingRelatedExpensesCurrent	1789000
CY2018Q4	iova	Manufacturing Related Expenses Current ManufacturingRelatedExpensesCurrent	2684000
CY2019Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	882000
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	489000
CY2019Q1	us-gaap	Accrued Rent Current AccruedRentCurrent	0
CY2018Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	124000
CY2019Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8489000
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11659000
CY2018Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	25300000
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	137500
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	57285
CY2019Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	45700000
CY2019Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y1M20D
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.99
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	15.52
CY2016Q2	iova	Common Stock Registered For Resale CommonStockRegisteredForResale	128500
CY2016Q2	iova	Number Of Share Options Or Share Units Exercised During Current Period NumberOfShareOptionsOrShareUnitsExercisedDuringCurrentPeriod	128500
CY2019Q1	iova	Payments For Legal Services PaymentsForLegalServices	100000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	466193000
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5846000
CY2019Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1000
CY2019Q1	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	71000
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	69000
CY2019Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	180000
CY2019Q1	iova	Stock Cancelled During Period Value Of Common Stock StockCancelledDuringPeriodValueOfCommonStock	-336000
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	434932000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	145481000
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4104000
CY2018Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0
CY2018Q1	iova	Stock Cancelled During Period Restricted Shares Value StockCancelledDuringPeriodRestrictedSharesValue	0
CY2018Q1	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	60000
CY2018Q1	iova	Common Stock Issued Upon Exercise Of Warrants Amount CommonStockIssuedUponExerciseOfWarrantsAmount	1826000
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5630000
CY2018Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	162092000
CY2019Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	300000
CY2018Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	386371000
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-26515000
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	292558000
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9957000
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0
CY2019Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	53000
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	230000
CY2019Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates</div></div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.38in; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include valuation of short-term investments, the useful lives of property and equipment, accounting for potential liabilities, the valuation allowance associated with the Company’s deferred tax assets, and the assumptions made in valuing stock instruments issued for services.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	123395113
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	123415576
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000041666
CY2019Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Reclassifications</div></div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.38in; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Certain amounts within the balance sheets for the prior period have been reclassified to conform with the current period presentation. These reclassifications had no impact on the Company's previously reported financial position or cash flows for any of the periods presented. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q1	iova	Payments For Legal Services PaymentsForLegalServices	100000
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward	The granted stock options vest in 12 quarterly installments (with 1/12th of the option shares having vested on the date of grant).
CY2019Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000041666
CY2019Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2016Q2	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	500000
CY2013Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	50000
CY2019Q1	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	32500
CY2019Q1	iova	Common Stock Shares Retained CommonStockSharesRetained	17500
CY2018Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	4589
CY2018Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1412
CY2018Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	144
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	466193000
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29090000
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17849000
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-26515000
CY2019Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	180000
CY2019Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6059000
CY2019Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1594000
CY2019Q1	us-gaap	Variable Lease Cost VariableLeaseCost	896000
CY2019Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	19000
CY2019Q1	us-gaap	Lease Cost LeaseCost	2509000
CY2019Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	5041000
CY2019Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	4589000
CY2019Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1413000
CY2019Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	144000
CY2019Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	0
CY2019Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	0
CY2019Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	11187000
CY2019Q1	iova	Operating Lease Present Value Adjustments OperatingLeasePresentValueAdjustments	-748000
CY2018Q4	iova	Lease Expiration Term LeaseExpirationTerm	P30M
CY2018Q4	us-gaap	Operating Leases Of Lessee Contingent Rentals Basis Spread On Variable Rate OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate	0.03
CY2019Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y10M9D
CY2019Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.084
CY2019Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1400000
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	10400000
CY2019Q1	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	335000
CY2018Q1	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1592000
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	368000
CY2019Q1	iova	Unrealized Gain Loss On Shortterm Investments UnrealizedGainLossOnShorttermInvestments	180000
CY2018Q1	iova	Unrealized Gain Loss On Shortterm Investments UnrealizedGainLossOnShorttermInvestments	0
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	434932000
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-36770000
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26515000
CY2019Q1	us-gaap	Assets Assets	461502000
CY2018Q4	us-gaap	Assets Assets	480821000
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y21D
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7078
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0259
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0
CY2018Q4	us-gaap	Operating Lease Payments OperatingLeasePayments	59000
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	10439000
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	10439000
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	10700000
CY2019Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6059000
CY2018Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0
CY2019Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4900000
CY2019Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4380000
CY2019Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4380000
CY2018Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0
CY2019Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5800000
CY2019Q1	iova	Increase Decrease In Operating Lease Liability And Right Of Use Asset IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset	1000000
CY2018Q4	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	6461
CY2018Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	0
CY2018Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0
CY2018Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	12606
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.31
CY2019Q1	iova	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-942000
CY2018Q1	iova	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	0
CY2019Q1	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 8. LEGAL PROCEEDINGS</div></div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; text-align: justify; text-indent: -0.5in; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.38in; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Class Action Lawsuit.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> On April 10, 2017, the SEC announced settlements with the Company and with other public companies and unrelated parties in the </div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">In the Matter of Certain Stock Promotion</div> investigation. The </div>Company’s<div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> settlement with the SEC is consistent with its previous disclosures (including in our Annual Report on Form 10-K that the Company filed with the SEC on March 9, 2017). On April 14, 2017, a purported shareholder filed a complaint seeking class action status in the United States District Court, Northern District of California for violations of the federal securities laws (<div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Leonard DeSilvio v. Lion Biotechnologies, Inc., et al., </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">case no. 3:17cv2086) against the Company and three of its former officers and directors. On April 19, 2017, a second class action complaint </div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">(Amra Kuc vs. Lion Biotechnologies, Inc., et al., </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">case no. 3:17-cv-2188) was filed in the same court. Both complaints allege, among other things, that the defendants violated the federal securities laws by making materially false and misleading statements, or by failing to make certain disclosures, regarding the actions taken by Manish Singh, the former CEO, and the former investor relations firm that were the subject of the </div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">In the Matter of Certain Stock Promotions</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> investigation. On July 20, 2017, the plaintiff in the </div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Kuc</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> case filed a notice to voluntarily dismiss that case. The court entered an order dismissing the </div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Kuc</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> complaint on July 21, 2017. On July 26, 2017, the court appointed a movant as lead plaintiff. On September 8, 2017, the lead plaintiff filed an amended complaint (</div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Jay Rabkin v. Lion Biotechnologies, Inc., et al., </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">case no. 3:17-cv-2086) seeking class action status that alleges, among other things, that the defendants violated federal securities laws by making materially false and misleading statements, or by failing to make certain disclosures, regarding the actions taken by Manish Singh and its former investor relations firm that were the subject of the </div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">In the Matter of Certain Stock Promotions</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> SEC investigation. On February 5, 2018, the court entered an order dismissing two of plaintiff’s six claims. As the result of mediation, on September 28, 2018, lead plaintiff filed an unopposed motion for settlement, the cost of which, if approved, is expected to be borne by the Company’s insurance carrier and would result in no loss to the Company. The court gave preliminary approval to the proposed settlement on November 30, 2018. A hearing was held on April 12, 2019 to determine whether the proposed settlement was fair, reasonable, and adequate, and whether the claims should be dismissed. On April 17, 2019, the court approved the final settlement, involving a payment of $3,250,000 by the Company’s insurance carrier to a settlement fund, awarded attorney’s fees and costs to be paid to plaintiff’s counsel from the settlement fund, approved the plan of allocation for settlement class members, and ordered that the claims against the Company should be dismissed with prejudice. The Company does not expect to incur any costs or expenses in connection with this settlement.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.38in; margin-right: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">  </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.38in; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Derivative Lawsuits.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> On December 15, 2017, a purported stockholder derivative complaint was filed by plaintiff Kevin Fong against the Company, as nominal defendant, and certain of the current and former officers and directors, and others, as defendants, in the U.S. District Court for the District of Delaware (case no. 1:17-cv-1806). The complaint alleges breaches of fiduciary duties, unjust enrichment, and violations of Section 14(a) of the Securities Exchange Act of 1934 and Rule 14a-9 promulgated thereunder arising from the SEC’s investigation in the </div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">In the Matter of Certain Stock Promotions</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> investigation and our April 10, 2017 settlement thereof, and seeks unspecified damages on behalf of the Company and injunctive relief. On March 28, 2018, a purported stockholder derivative complaint was filed by plaintiff Nazeer Khaleeluddin on behalf of the Company, against the Company, as nominal defendant, and certain of the Company’s current and former officers and directors, and others, as defendants, in the U.S. District Court for the District of Delaware (case no. 1:18-cv-00469). The complaint alleges, among other things, violations of securities law, breach of fiduciary duty, aiding and abetting, waste of corporate assets, and unjust enrichment. The complaint is based on claims arising from the SEC’s investigation in the </div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">In the Matter of Certain Stock Promotions</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> investigation and the Company’s April 10, 2017 settlement thereof, and seeks unspecified damages on behalf of our company and injunctive relief. On May 1, 2018, the court consolidated this case with the aforementioned purported stockholder derivative case filed by plaintiff Kevin Fong. The Company intends to vigorously defend against the foregoing complaints. Based on the early stage of the litigation, it is not possible to estimate the amount or range of possible loss that might result from an adverse judgment or a settlement of these matters.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.38in; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Solomon Capital, LLC.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> On April 8, 2016, a lawsuit titled </div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Solomon Capital, LLC, Solomon Capital 401(K) Trust, Solomon Sharbat and Shelhav Raff v. Lion Biotechnologies, Inc.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> was filed by Solomon Capital, LLC, Solomon Capital 401(k) Trust, Solomon Sharbat and Shelhav Raff against the Company in the Supreme Court of the State of New York, County of New York (index no. 651881/2016). The plaintiffs allege that, between June and November 2012 they provided to the Company $0.1 million and that they advanced and paid on our behalf an additional $0.2 million. The complaint further alleges that the Company agreed to (i) provide them with promissory notes totaling $0.2 million, plus interest, (ii) issue a total of 111,425 shares to the plaintiffs (before the 1-for-100 reverse split of our common stock effected in March 2013), and (iii) allow the plaintiffs to convert the foregoing funds into our securities in the next transaction. The plaintiffs allege that they should have been able to convert their advances and payments into shares of our common stock in the restructuring that was affected in May 2013. Based on the foregoing, the plaintiffs allege causes for breach of contract and unjust enrichment and demand judgment against the Company in an unspecified amount exceeding $1.5 million, plus interest and attorneys’ fees. On June 3, 2016, the Company filed an answer and counterclaims in the lawsuit. In its counterclaims, the Company alleges that the plaintiffs misrepresented their qualifications to assist the Company in fundraising and that they failed to disclose that they were under investigation for securities laws violations. The Company is seeking damages in an amount exceeding $0.5 million and an order rescinding any and all agreements that the plaintiffs contend entitled them to obtain stock in the Company. On April 19, 2017, the court granted plaintiffs’ counsel’s motion to withdraw from the case. On May 25, 2017, plaintiffs filed a notice that they had hired new counsel. On June 7, 2017, the judge presiding over the case recused herself because of a conflict of interest arising from her relationship with plaintiffs’ new attorneys and the case was subsequently assigned to a new judge.  On April 20, 2018, the court held a hearing regarding plaintiff’s motion to dismiss the Company’s amended counterclaims and affirmative defense for fraudulent inducement. On August 15, 2018, the court entered an order granting the plaintiffs’ motion and dismissed the Company’s amended counterclaims and eleventh affirmative defense for fraudulent inducement without leave to amend. On September 14, 2018, the Company filed a notice of appeal related to this order, and on November 5, 2018, the Company filed its memorandum of law in support of its appeal of the order dismissing the Company’s amended counterclaims and affirmative defense for fraudulent inducement. On January 2, 2019, plaintiffs filed their memorandum of law in opposition to the appeal. On January 18, 2019, the Company filed its reply brief in support of its appeal of the order dismissing its amended counterclaims and affirmative defense for fraudulent inducement. On April 4, 2019, the appellate court ordered that the Company’s amended counterclaims and its affirmative defense for fraudulent inducement be reinstated.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.38in; margin-right: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.38in; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company intends to vigorously defend the complaint and pursue its counterclaims.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.38in; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Litigation Involving Dr. Steven Fischkoff.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> On June 13, 2017, in an action titled </div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Steven Fischkoff v. Lion Biotechnologies, Inc. and Maria Fardis</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">, Dr. Steven Fischkoff, our former Vice President and Chief Medical Officer, filed a lawsuit against the Company in the Supreme Court of the State of New York, County of New York. Dr. Fischkoff was dismissed by the Company on March 28, 2017. Dr. Fischkoff was terminated “for cause” as that term is defined in his employment agreement. In his complaint, Dr. Fischkoff alleges breaches of his employment agreement and violation of New York Labor Law for failure to pay monies purportedly owed to him, and seeks to recover amounts including severance pay and retention bonus (totaling $300,000), a prorated incentive bonus, and amounts relating to unvested options to 150,000 shares of our common stock, together with prejudgment interest, costs, expenses and attorneys’ fees. On July 5, 2017, we filed a removal petition and removed the lawsuit to the United States District Court for the Southern District of New York, where the case has been assigned case no. 1:17-cv-05041. On July 14, 2017, the Company filed a partial answer and counterclaims against Dr. Fischkoff, denying his allegations, and alleging breach of contract and related claims, breach of fiduciary duty, and state and federal trade secret misappropriation and related claims, and sought a temporary restraining order and preliminary injunction against Dr. Fischkoff. On July 18, 2017, the court issued a temporary restraining order against Dr. Fischkoff requiring him to return our materials, prohibiting him from disclosing or using the Company’s materials, and granting expedited discovery. On June 25, 2018, pursuant to a stipulation between the parties, the court entered a permanent injunction prohibiting Dr. Fischkoff from disclosing, possessing, or using any of the Company’s proprietary materials or trade secrets. On July 5, 2018, the court entered an order dismissing two of Dr. Fischkoff’s claims against the Company and Dr. Fardis. On October 18, 2018, Dr. Fischkoff amended his complaint to assert a new claim for defamation arising from SEC filings in which the Company provided the information about this litigation.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.38in; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company intends to vigorously defend against Dr. Fischkoff’s lawsuit and pursue the Company’s counterclaims. Based on the current stage of the litigation, it is not possible to estimate the amount or range of (i) a possible loss that might result from an adverse judgment or settlement of this action, or (ii) the potential recovery that might result from a favorable judgment or a settlement of this action.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.38in; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Other Matters.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> During the second quarter of 2016, warrants representing 128,500 shares were exercised. The 128,500 shares of common stock had previously been registered for re-sale. However, the Company believes that these 128,500 warrant shares were sold by the holders in open market transactions in May 2016 at a time when the registration statement was ineffective. Accordingly, those sales were not made in accordance with Sections 5 and 10(a)(3) of the Securities Act of 1933, as amended, and the purchasers of those shares may have rescission rights (if they still own the shares) or claims for damages (if they no longer own the shares). The amount of any such liability is uncertain and as such, an accrual for any potential loss has not been made. The Company believes that any claims brought against it would not result in a material impact to the Company’s financial position or results of operations. The Company has not accrued a loss for a potential claim associated with this matter as it is unable to estimate any at this time.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">  </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.38in; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In connection with the Company’s reincorporation from Nevada to Delaware in 2017, the Company (as a Delaware corporation) untimely filed a post-effective amendment to adopt a Form S-8 registration statement that the Company filed (as a Nevada corporation) to register the shares underlying the 2011 Plan. Before the Company filed the required post-effective amendment, options to purchase 200,000 shares were exercised under the 2011 Plan. The effect of the delayed post-effective amendment filing on the 200,000 option shares is uncertain, but the issuance and sale of the shares may not have been in compliance with the Form S-8 registration statement. The existence of any liability to the Company, and the amount of any such liability to the Company, as a result of the issuance of the 200,000 shares is uncertain. Accordingly, no accrual for a potential claim has been made by the Company in its financial statements.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.38in; margin-right: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.38in; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company may be involved, from time to time, in legal proceedings and claims arising in the ordinary course of our business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues amounts, to the extent they can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that it believes will result in a probable loss. While there can be no assurances as to the ultimate outcome of any legal proceeding or other loss contingency involving the Company, management does not believe any pending matter will be resolved in a manner that would have a material adverse effect on our financial position, results of operations or cash flows.</div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	123395113
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	123415576
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	an amendment to increase the number of options or other awards that can be granted to any one person during a twelve (12) month period from 50,000 shares to 300,000 shares
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	39986000
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	26877000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-36950000
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-26515000
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-39986000
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-26877000
CY2019Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	0
CY2019Q1	iova	Non Cash Lease Expense NonCashLeaseExpense	1424000
CY2018Q1	iova	Non Cash Lease Expense NonCashLeaseExpense	0
CY2019Q1	dei	Document Type DocumentType	10-Q
CY2019Q1	dei	Amendment Flag AmendmentFlag	false
CY2019Q1	dei	Document Period End Date DocumentPeriodEndDate	2019-03-31
CY2019Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2019Q1	dei	Entity Registrant Name EntityRegistrantName	IOVANCE BIOTHERAPEUTICS, INC.
CY2019Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001425205
CY2019Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2019Q1	dei	Trading Symbol TradingSymbol	IOVA
CY2019Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	123514231
CY2019Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019Q1	dei	Entity Small Business EntitySmallBusiness	false

Files In Submission

Name	View Source	Status
0001144204-19-024279-index-headers.html	Edgar Link	pending
0001144204-19-024279-index.html	Edgar Link	pending
0001144204-19-024279.txt	Edgar Link	pending
0001144204-19-024279-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
iova-20190331.xml	Edgar Link	completed
iova-20190331.xsd	Edgar Link	pending
iova-20190331_cal.xml	Edgar Link	unprocessable
iova-20190331_def.xml	Edgar Link	unprocessable
iova-20190331_lab.xml	Edgar Link	unprocessable
iova-20190331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv519830_10q.htm	Edgar Link	pending
tv519830_ex31-1.htm	Edgar Link	pending
tv519830_ex31-2.htm	Edgar Link	pending
tv519830_ex32-1.htm	Edgar Link	pending
tv519830_ex32-2.htm	Edgar Link	pending
tv519830_img01.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IOVA
IOVANCE BIOTHERAPEUTICS, INC. Stock $iova

2019 Q2 Form 10-Q Financial Statement

#000114420419024279 Filed on May 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IOVA IOVANCE BIOTHERAPEUTICS, INC. Stock $iova

2019 Q2 Form 10-Q Financial Statement

#000114420419024279 Filed on May 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IOVA
IOVANCE BIOTHERAPEUTICS, INC. Stock $iova